Breast Cancer: KOL Insight 
How is biosimilar trastuzumab expected to fare in breast cancer?
Biosimilar trastuzumab is now available in Europe, and key opinion leaders (KOLs) weigh in on how this product is expected to fare after years of Herceptin domination in the HER2-positive space. KOLs discuss how Roche’s Perjeta will be used in the future and whether the APHINITY trial results will change prescribing habits. Experts also give their views on whether the launch of Puma Biotechnology’s Nerlynx in the US has been successful. Meanwhile, in the HER2-negative/HR-positive space, experts provide insights on Pfizer’s first-to-market CDK4/6 inhibitor, Ibrance, and whether Novartis’ Kisqali and Eli Lilly’s Verzenio are succeeding in taking a slice of the market. The US launch of AstraZeneca/Merck & Co.’s Lynparza is discussed in BRCA-mutated triple-negative breast cancer and the potential usage of PD-1/PD-L1 checkpoint inhibitors is also explored. Twelve US and EU KOLs offer their candid insights on these issues and more.
The table of contents
The key business questions answered
The key KOL quotes
See the therapies covered
Find out who the 6 EU & 6 US KOLs are
Review an extract from the report - 1 drug profile
Biosimilar trastuzumab has been launched in Europe. How do KOLs view these products and will patient switching from the branded product become commonplace?
Perjeta is approved as an adjuvant therapy for HER2-positive disease in the US. How do KOLs perceive the APHINITY trial results and will they impact prescribing?
Despite its US launch, Nerlynx has received a negative opinion in Europe. How do US KOLs view Nerlynx’s launch and how will this product be used going forward?
How successful have the Kisqali and Verzenio launches been? And can Pfizer’s Ibrance retain its position as the preferred CDK4/6 inhibitor?
How could the alpha specific PI3 kinase inhibitors, alpelisib and taselisib be positioned in the treatment paradigm? KOLs offer their views on these agents.
Lynparza is now available as a therapy for BRCA-mutated, HER2-negative breast cancer. How is this product currently being prescribed and will usage evolve in the future?
Is talazoparib considered a threat to Lynparza? How do KOLs view talazoparib’s EMBRACA data and does this agent have any particular advantages over Lynparza?
KOLs discuss how checkpoint inhibitors may be used in triple-negative breast cancer (TNBC). What are KOLs’ thoughts on these agents and how do they envisage these products being incorporated in the future?
“Kadcyla has really got an established second-line place, because pertuzumab and Herceptin and Taxotere are approved as first-line on relapse, then there's a very clear spot in which Kadcyla comes in as second-line.” EU Key Opinion Leader
“We give Ibrance to anybody who has first-line metastatic ER-positive breast cancer that doesn't have a visceral crisis needing chemotherapy.” US Key Opinion Leader
Sample of therapies covered
Herceptin (trastuzumab; Roche)
Kadcyla (ado-trastuzumab emtansine; Roche)
Perjeta (pertuzumab; Roche)
Tykerb/Tyverb (lapatinib; Novartis)
Nerlynx (neratinib; Puma Biotechnology)
Afinitor (everolimus; Novartis)
Ibrance (palbociclib; Pfizer)
Kisqali (ribociclib; Novartis)
Verzenio (abemaciclib; Eli Lilly)
Lynparza (olaparib; AstraZeneca/Merck & Co.)
margetuximab (MGAH 22; MacroGenics)
alpelisib (BYL 719; Novartis)
taselisib (GDC 0032; Roche)
ipatasertib (GDC 0068; RG 7440; Roche)
entinostat (SNDX 275; Syndax)
talazoparib (BMN 673; Pfizer)
Zejula (niraparib; Tesaro/Merck & Co.)
veliparib (ABT 888; AbbVie)
Keytruda (pembrolizumab; Merck & Co.)
Tecentriq (atezolizumab; Roche)
Bavencio (avelumab; Merck Group/Pfizer)
KOLs from North America
Dr. Adam M. Brufsky, MD, PhD is Professor of Medicine at the University of Pittsburgh School of Medicine, Pittsburgh, P
Dr. Reshma Mahtani, DO is Assistant Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, FL
Dr. Ruta D. Rao, MD is Associate Professor of Medicine, Director, Coleman Comprehensive Breast Center and Director, Hematology & Oncology Fellowship Program at Rush University Medical Center, Chicago, IL
Dr. Sara Tolaney, MD, MPH is an Instructor of Medicine at Harvard Medical School and Attending Physician at the Dana-Farber Cancer Institute, Boston, MA
Dr. Charles L. Vogel, MD is Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, FL
Anonymous, US KOL is an Assistant Professor of Medicine at a leading US institute
KOLs from Europe
Dr. Ahmad Awada, MD is Head of the Medical Oncology Clinic at Jules Bordet Cancer Institute, Brussels, Belgium
Dr. Thomas Bachelot, MD is Head of the Breast Cancer Unit and the Clinical Trial Unit at the Centre Leon Berard, Lyon, France
Dr. Richard Baird, MA MBBS PhD FRCP is Academic Consultant in Experimental Cancer Therapeutics, University of Cambridge and Honorary Consultant in Medical Oncology, Addenbrooke’s Hospital, Cambridge, UK
Dr. Remy Salmon, MD is former Head of the Department of Surgery at the Curie Institute and a specialist in the management of breast cancer at the Saint John of God Foundation Oudinot Clinic, Paris, France
Dr. Adrian L. Harris, MD, DPhil is Professor of Medical Oncology at the University of Oxford and Director of the Cancer Research UK Medical Oncology Unit, London, England
Anonymous, German KOL is the Head of Division at a leading German University Hospital
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.